Biotech, Trinity
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB),
Trinity Biotech Shares Rise After Update on Next-Gen Blood-Sugar Monitoring Device
Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes management that measures blood sugar levels in real time.
Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based diagnostic company with a market capitalization of $23.7 million and current trading price of $1.32, is evaluating the potential effects of a recent ...
Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...
Stocktwits on MSN1d
TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for ...
Investors have been closely monitoring Trinity Biotech's financial health and market position, as the company grapples with the headwinds that have led to this decline. With a significant debt burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback